We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Corvidia’s shareholders will receive an upfront payment of $725 million and will be eligible for future payments that could total $2.1 billion. Read More
The European Investment Bank is making available up to $113 million in financing for BioNTech’s BNT162, a messenger RNA-based vaccine, and the scaling up of manufacturing capacity for it in Europe. Read More
Fujifilm said it plans to invest $928 million to double production capacity at its biologics manufacturing facility in Denmark to supply bulk drug substances for future COVID-19 therapies and other products. Read More
Partly in response to the COVID-19 pandemic, HHS is partnering with a Boston-based drugmaker to create a domestic supply chain that doesn’t rely on foreign sources for active pharmaceutical ingredients. Read More
Oxford Biomedica has signed a five-year collaboration agreement with the Vaccines Manufacturing and Innovation Center (VMIC) to manufacture viral vector-based vaccines. Read More
The funding also includes a delivery of 10 million doses this year that can be used in phase 2/3 clinical trials or under Emergency Use Authorization. Read More
Inovio Pharmaceuticals has sued its primary vaccine manufacturer VGXI for alleged breach of contract over production of Inovio’s COVID-19 vaccine candidate. Read More